179 related articles for article (PubMed ID: 8449599)
1. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
[TBL] [Abstract][Full Text] [Related]
2. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
6. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
8. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
10. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
Masson P; Pålsson B; Andren-Sandberg A
Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
15. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
[TBL] [Abstract][Full Text] [Related]
18. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
19. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study.
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Cancer; 1991 Jul; 68(1):149-52. PubMed ID: 2049735
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
